XVARY Composite Score
/ 100
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
It makes drugs for cystic fibrosis. That means you are buying a bet on one disease target.
How it gets paid
Last year Sionna Therapeutics made n/a in revenue. NBD1 stabilizers was the main engine at $0, or 40% of sales.
What just happened
The latest quarter printed a -$1.43 EPS loss, and there is still no revenue cushion.
At a Glance
N/a balance sheet
-$15.99 fy2024 eps est
~$2B market cap
Small cap
NASDAQ
What They Do
It makes drugs for cystic fibrosis. That means you are buying a bet on one disease target.
More than a decade on NBD1, the CFTR protein pocket, is the moat. That is years of chemistry aimed at one target, not a broad sales machine. You are betting that small, specific know-how beats bigger rivals with approved drugs.
How They Make Money
n/a
annual revenue
NBD1 stabilizers
$0
Complementary CFTR modulators
$0
F508del correction programs
$0
Preclinical platform work
$0
The Products That Matter
Lead oral NBD1 stabilizer
SION-719
mid-2026 readout
This is one of two assets carrying the equity story. Your timeline here is measured in trial milestones, not sales growth or margin expansion.
lead asset
Second oral NBD1 stabilizer
SION-451
mid-2026 readout
This is the second shot on goal, but it targets the same underlying protein problem. Two programs helps. It does not turn one scientific thesis into two independent ones.
same biology
Cash runway
balance sheet
$310.3M cash
For a company with no product sales, the balance sheet functions like a product. It funds the trials, the staff, and the wait until the data either creates value or forces dilution.
runway
Key Numbers
-$15.99
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial Health
n/a
Strength
- balance sheet grade n/a
n/a — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
The latest quarter printed a -$1.43 EPS loss, and there is still no revenue cushion.
EDGAR shows the latest quarter at -$1.43 per share. That is a pure cash-burn print with no sales line to absorb it.
$1.43
eps
n/a
n/a
n/a
n/a
EPS loss
The -$1.43 loss per share matters because it shows the company still has no sales to soften the burn.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The main risk is simple: mid-2026 data disappoints or slips. With no product revenue under the story, SION-719 and SION-451 are not side projects. They are the story.
Med
Lead-trial disappointment
Top-line data for SION-719 and SION-451 is expected mid-2026. If the efficacy or safety picture disappoints, there is no product revenue to soften the hit.
A weak readout would pressure the entire roughly $2B valuation because most of that value rests on future probability, not current cash flow.
Med
Dilution before proof
Sionna filed a $250M ATM shelf on March 2, 2026. That gives management flexibility. It also gives the market a standing reminder that new shares can appear.
If the ATM gets used aggressively before the key readout, you fund survival by diluting the upside you were waiting for.
Med
Cash burn meets delay risk
The company lost $75M in 2025 and ended with $310.3M in cash. That looks workable today. It gets less comfortable if timelines slip or trial costs climb.
A delay hurts twice — first by pushing out the value inflection, then by increasing the odds of a raise under worse terms.
Med
The bar is set by Vertex, not by hope
Sionna is pursuing a cystic fibrosis market where the incumbent already dominates. Positive data alone may not be enough. The data probably needs to look differentiated, not just acceptable.
Even if the science works, the commercial path can still be narrower than early investors expect.
With no product revenue and a $250M ATM in place, the path from $310.3M cash to mid-2026 data matters almost as much as the data itself.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Catalyst
Mid-2026 lead data for SION-719 and SION-451
This is the screensaver event. Two assets. One readout window. A large part of the roughly $2B valuation is parked here.
Dilution
Whether the $250M ATM stays optional or becomes active
The shelf exists. The real question is timing. Selling stock before proof changes the risk-reward math for you immediately.
Runway
Cash versus the $75M annual loss profile
If burn starts rising from the 2025 level, the comfort provided by $310.3M cash shrinks faster than investors want.
Timeline
The next earnings update around May 18, 2026
You are not reading earnings for revenue momentum. You are reading them for burn, timing, and any hint the readout calendar is moving.
Institutional Activity
institutional ownership data for SION is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$38
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive